Search Results

You are looking at 1 - 10 of 155 items for :

  • Refine by Access: All Content x
Clear All

Monoklonális ellenanyag-alapú terápia myeloma multiplexben

Monoclonal antibody-based therapy in multiple myeloma

Hematológia–Transzfuziológia
Authors:
Apor Hardi
,
András Kozma
,
Andrea Ceglédi
,
Ágnes Tomán
,
András Bors
,
Hajnalka Andrikovics
, and
Gábor Mikala

Oncol 2018; 8: 163. 2 Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol 2016; 43: 676

Restricted access

(47), 1858–1864. [Hungarian] 2 Kyle, R. A., Gertz, M. A., Witzig, T. E., et al.: Review of 1,027 patients with newly diagnosed multiple myeloma. Mayo Clin. Proc

Restricted access

Venetoclax alkalmazása myeloma multiplexben

The use of venetoclax in multiple myeloma

Hematológia–Transzfuziológia
Authors:
Virág Réka Szita
and
Gergely Varga

Irodalom 1 Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, et al. Extensive Immunoglobulin Production Sensitizes Myeloma Cells for

Open access

An outbreak of simultaneously occurring haemangiomas, leiomyosarcoma and myeloma was observed in a commercial layer flock in China. The sick chickens were extremely thin and dehydrated. Scattered haemangiomas were found on the claws, breast and wings. At necropsy, haemangiomas and some other nodular tumours were also found in the internal organs. In addition, diffuse enlargement of the liver and spleen appeared in some birds. Histopathologically, haemangiomas were typically cavernous haemangiomas and haemangioendothelioma. In the diffusely swollen liver and spleen, multifocal or widespread marrow tumour cells filled with ball-like acidophilic particles in cytosol were observed, which are the characteristic pathological changes of avian myelocytomatosis. The nodular tumour cells formed by muscle bundles were of variable size, irregular shape, poorly differentiated and malaligned. Immunohistochemistry for vimentin, cytokeratin, actin (smooth muscle) and actin (sarcomeric) and Masson’s staining confirmed the different cell lineage of the nodular tumour, thus leading to the diagnosis of leiomyosarcoma. The seroprevalence of avian leukosis subgroup J (ALV-J) antibodies was 13.46% (7/52), while ALV-A/B and reticuloendotheliosis virus (REV) antibodies were not detectable. The DF-1 cells inoculated by virus extracted from liver samples from 24 infected chickens were cultured and the group-specific antigen (GSA) was identified by ELISA. All samples were positive for ALV, which was further identified as ALV-J by immunofluorescence assay (IFA). PCR analysis revealed that three isolates of ALV-J proviral sequence were close to the HPRS-103 prototype strain and other Chinese field strains isolated in recent years, while one isolate (DP01) had a lower homology with them. This is the first report that ALV-J infection caused the simultaneous occurrence of haemangiomas, leiomyosarcoma and myeloma in a commercial layer flock.

Restricted access

Agyi myeloma képét utánzó toxoplasmosis

Toxoplasmosis masquerading as cerebral myeloma

Hematológia–Transzfuziológia
Authors:
Eszter Nagy
,
Andrea Ceglédi
,
Bálint Gergely Szabó
,
Botond Lakatos
,
Viktória Kiss Anita
,
András Kozma
,
Attila Balogh
,
Hajnalka Rajnai
,
Péter Reményi
, and
Gábor Mikala

A legtöbb malignus hematológiai betegségben, így myeloma multiplexben is gyakori szövődménynek számítanak a fertőzések, nemcsak a betegség okozta immundefektus, hanem a daganatellenes kezelések immunszuppresszív hatása miatt is [ 1 ]. A

Restricted access

Betegutak myeloma multiplexben – egy felmérés tanulságai

Patients’ journey in multiple myeloma – lessons from a survey

Hematológia–Transzfuziológia
Authors:
László Váróczy
,
Eszter Kun
, and
Sándor Tóth

Irodalom 1 Engelhardt M, Terpos E, Kleber M, et al.: European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple

Open access
Orvosi Hetilap
Authors:
Gergely Varga
,
Gábor Mikala
,
László Váróczy
, and
Árpád Illés

References 1 Engelhardt, M., Terpos, E., Kleber, M., et al.: European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed

Open access
Orvosi Hetilap
Authors:
Katalin Molnár
,
István Karádi
,
István Sugár
,
Zoltán Sápi
,
Márta Marschalkó
,
Éva Pálinger
,
Zsuzsanna Darvas
,
Péter Pócza
,
András Falus
,
András Vereczkei
, and
Judit Várkonyi

Bayer-Garner, I. B., Smoller, B. R.: The spectrum of cutaneous disease in multiple myeloma. J. Am. Acad. Dermatol., 2003, 48 , 497–450. Smoller B. R

Restricted access

Ígéretes új eredmények a myeloma multiplex első vonalbeli kezelésében

Promising new developments in first-line therapy of multiple myeloma

Hematológia–Transzfuziológia
Authors:
Gábor Mikala
,
Andrea Ceglédi
, and
Apor Hardi

Irodalom 1 Liu C, Ghobrial I, Bustoros M, et al. Phase II trial of combination of elotuzumab, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma

Restricted access
Orvosi Hetilap
Authors:
Tamás Szendrei
,
Márk Plander
,
Zsuzsanna Szabó
,
László Kereskai
,
Béla Kajtár
,
Gergely Papp
, and
János László Iványi

References 1 Davies FE. Is molecular remission the goal of multiple myeloma therapy? Hematology Am Soc Hematol Educ Program 2017; 2017: 205

Open access